• Illinois: Last week, Abbott Laboratories closed its $21 billion acquisition of Exact Sciences, a cancer screening company. The deal was initially announced in November and is Abbott's largest deal in almost a decade. According to Modern Healthcare, the acquisition allows Abbott to expand its footprint in the global cancer diagnostics market through Exact's colorectal cancer screening test Cologuard and other cancer diagnostic tools. "Abbott's global scale, track record of operational and commercial excellence, and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments," said Abbot's chair and CEO Robert Ford. "With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care." Exact is now a subsidiary of Abbott and will boost its total diagnostic sales to over $12 billion annually, with an additional $3 billion in incremental sales expected in 2026. (Dubinsky, Modern Healthcare, 3/20; Abbott press release, 3/23)
• Maryland: FDA will hold a public hearing to gather feedback about its Commissioner's National Priority Voucher Program on June 12. The program was initially launched in June 2025 and designed to accelerate FDA review of drugs and biologics that are "aligned with U.S. national priorities." So far, 18 products have received vouchers through the program, and four have received approval, including two new oncology therapies. The hearing will be held at FDA's White Oak campus in Silver Spring, Maryland, and will include virtual attendance options. Interested stakeholders have until May 1 to request to speak at the hearing. Written comments on the program will also be accepted through June 27. (Jeffries, Becker's Hospital Review, 3/23)
• New York: According to a new report from the Guttmacher Institute, U.S. abortion rates have remained largely steady despite strict bans in 13 states. In 2025, there were an estimated 1,126,000 abortions in the United States, a less than 0.2% change from 2024. Telehealth has been a key way people are accessing abortion care, especially in states with bans. The number of abortions provided through telehealth increased from roughly 72,000 in 2024 to 91,000 in 2025. Meanwhile, the number of people who traveled for abortion care fell to 142,000 in 2025, down from 154,000 in 2024. "It makes sense that we'd see a decline in travel [for abortion]," said Isaac Maddow-Zimet, a data scientist at Guttmacher. "Because people accessing abortion care through telehealth in general then no longer need to travel for care. So it's not surprising, per se, but it is the first time that we’ve been able to put out specific numbers showing this shift." (Simmons-Duffin, NPR, 3/24; Choi, The Hill, 3/24)

The implications of the Supreme Court's decision to overturn Roe v. Wade and Planned Parenthood v. Casey are far-reaching. Check out our insights and interactive maps to see which groups will be most impacted by new abortion restrictions in each state.